2022 American Transplant Congress
Renal Transplantation and Statins Effects on Dyslipidemia in Renal Transplant Recipients
*Purpose: to review the effect of renal transplantation and adding of statins on dyslipidemia in renal transplant recipients.*Methods: A single center experience retrospective study of…2022 American Transplant Congress
Efficacy and Safety of PCSK-9 Inhibitor, Evolocumab for Lipid Management in Kidney Transplant Recipients
*Purpose: Dyslipidemia is common in kidney transplant recipients (KTRs). KDIGO guidelines suggest all KTRs should be treated with statins due to the high risk of…2022 American Transplant Congress
Low-Dose Aspirin is More Critical Than Statins in Preventing Transplant Renal Artery Stenosis
Urology, Henan Provincial People's Hospital, Zhengzhou, China
*Purpose: To explore the clinical value of low-dose aspirin (100mg) and statins (10 ~ 20mg) in the prevention of transplant renal artery stenosis (TRAS).*Methods: A…2022 American Transplant Congress
Evolution of Pretransplant Cardiac Risk Factor Burden and Major Adverse Cardiovascular Events in Liver Transplant Recipients Over Time
Northwestern Medicine, Chicago, IL
*Purpose: The aim of this study is to evaluate the evolution of MACE and pre-LT cardiac risk factors in LTRs over time.*Methods: This is a…2022 American Transplant Congress
A Single-Center Cross-Sectional Analysis of Lipid Management in Kidney Transplant Recipients: Is It Time to Reassess KDIGO Guidelines?
1Renal Division, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA
*Purpose: Cardiovascular disease remains the leading cause of mortality after kidney transplant, accounting for more than 30% of total deaths. Dyslipidemia is common following transplantation,…2022 American Transplant Congress
Efficacy of a Multispecialty, Multidisciplinary Strategy to Improve the Level of Awareness and Control of Cardiovascular Risk Factors After Liver Transplantation
Hospital Clinic, Barcelona, Spain
*Purpose: Although liver transplant (LT) recipients are at high cardiovascular risk, the management of cardiovascular risk factors (CVRF) after LT is far from optimal. We…2021 American Transplant Congress
Evaluation of Safety and Efficacy of PCSK9 Inhibitors in Solid Organ Transplant Recipients: Experience at a Large Multi-organ Transplant Center
*Purpose: The aim of the study was to characterize the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in solid organ transplant…2020 American Transplant Congress
Selectively Transplanting Moderately to Severely Macrosteatotic Grafts: Does Recipient Metabolic Environment Affect Outcomes?
Department of Surgery, Thomas Jefferson University, Philadelphia, PA
*Purpose: As incidence of Non-Alcoholic Steatohepatitis (NASH) cirrhosis rises, organ utilization remains stagnant. Recently, it has been shown that selective utilization of >30% macrosteatotic grafts…2020 American Transplant Congress
Cardiovascular Improvement after Pancreatic Transplantation
*Purpose: Cardiovascular disease is a common cause of mortality in patients with uncontrolled diabetes. The purpose of this study is to assess whether patients receiving…2020 American Transplant Congress
Hyperlipidemia Prevalence and Treatment in Pediatric Kidney Transplantation
1Children's Healthcare of Atlanta, Atlanta, GA, 2Emory University, Atlanta, GA
*Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in adult survivors of pediatric kidney transplantation. This study describes the prevalence of hyperlipidemia and…
American Transplant Congress abstracts